Inspirna

    Inspirna (formerly Rgenix) is a privately-held cancer therapeutics company focused on the discovery and development of novel cancer drugs that target key pathways in cancer progression. Using a mRNA-based target discovery platform developed by Inspirna's scientific co-founders at The Rockefeller University, the company is developing several first-in-class drug candidates to treat cancers of high unmet need. The company brings together distinguished scientific founders and a leadership team with a seasoned Board comprised of experienced drug developers. The company is funded by leading biotechnology investors, including Novo A/S, Sofinnova Partners, and Alexandria Venture Investments.

    SofinnovaCapital

    The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.

    SofinnovaMD Start

    The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.

    SofinnovaCrossover

    The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.

    SofinnovaIndustrial Biotech

    Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.

    SofinnovaTelethon

    The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.

    Welcome to our new website – a fresh look that represents a new SofinnovaFind out more